In contrast, the Ellis study [ 42] recruited patients who were treated with an AI with 24 or more weeks of progression-free survival or who had a relapse after 2 or more years of adjuvant AI.
Patients were evaluated radiologically by plain radiographs every 4 6 weeks for progression of healing, local recurrence and deformity resulting from partial fusion of the epiphysis.
Quantitative data revealed significant differences at two time points, at 5 and 12 weeks of tumor progression in 202Mul/DN mice versus 202Mul mice.
We show that the injection of a dose of 500 U of collagenase in the rat's knee leads, after six weeks of disease progression, to a set of both histopathological and nociceptive changes that are consistent with the development of OA-like alterations, along with changes in the sensory innervation of the affected joint.
The treatment was repeated every 2 weeks until progression of the disease, the development of unacceptable toxicity, or patient withdrawal from the study.
Intravenous fotemustine was administrated at 100 mg/m every week for 3 consecutive weeks followed by a 5-week rest period; subsequently, an infusion was done every 3 weeks until progression of the disease or unacceptable toxicity or until a maximum of 12 cycles was reached.
Following an incubation period of about 6 8 weeks, the risk of progression to TB is highest shortly after infection, followed by an exponential decline in subsequent years [ 57, 58].
This cycle was given every 2 weeks until progression of the disease.
Temozolomide was administered at 150 mg m−2 day−1, for 5 days every 4 weeks until progression of disease (PD), unacceptable toxicity or patient's refusal.
cisplatin, 1000 mg m−2 i.v. gemcitabine, and 2500 mg m−2 i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred.
cisplatin, 1000 mg m−2 i.v. gemcitabine, and 2500 mg m−2 i.v. treosulfan on days 1 and 8. Therapy was repeated every 5 weeks until progression of disease occurred.
